Kalle Mattila - UTU Research Portal

Kalle Mattila

- ,
Clinical Oncology (Department of Clinical Medicine)
- Docent,
Department of Clinical Medicine (Faculty of Medicine)

kalmat@utu.fi

1 of 4

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma (2026)
- BMC Cancer
Ejder, Patric; Jespersen, Henrik; Hernberg, Micaela; Ny, Lars; Carneiro, Ana; Ellegård, Sander; Mattila, Kalle; Bagge Olofsson, Roger; Fountoukidis, Georgios; Brandberg, Yvonne; Mandala, Mario; O’Carrigan, Brent; Schilling, Bastian; Aranche, Ana; Hamid, Omid; Berglund, Anders; Helgadottir, Hildur; Ullenhag, Gustav
Tumor cell FAP orchestrates EMT and immune suppression in aggressive localized ccRCC (2026)
- Theranostics
Pellinen, Teijo; Luomala, Lassi; Mattila, Kalle E.; Hemmes, Annabrita; Välimäki, Katja; Arjama, Mariliina; Brück, Oscar; Paavolainen, Lassi; Kankkunen, Elisa; Nisén, Harry; Järvinen, Petrus; Castillon, Leticia; Vanharanta, Sakari; Vainio, Paula; Kallioniemi, Olli; Jaakkola, Panu M.; Mirtti, Tuomas
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma (2025)
- BJUI COMPASS
Brännbäck, Anna; Mustonen, Ivan; Laajala, Teemu D.; Vainio, Paula; Lindskog, Magnus; Kjellman, Anders; Lundgren, Per-Olof; Jaakkola, Panu M.; Mattila, Kalle E.
Effectiveness of External Hemorrhage Compression Device of the Abdominal Aorta in Hemorrhagic Shock: A Systematic Review of the Literature (2025)
- Journal of Special Operations Medicine
Kuusisto, Jaakko; Mattila, Kalle; Iirola, Timo; Heino, Anssi
Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma (2024)
- Cancer Medicine
Luomala, Lassi; Mattila, Kalle; Vainio Paula; Nisén, Harry; Pellinen, Teijo; Lohi, Jouni; Laajala, Teemu D.; Järvinen, Petrus; Koskenniemi, Anna-Riina; Jaakkola, Panu; Mirtti, Tuomas
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study (2024)
- Future Oncology
Mattila, Kalle E; Tiainen, Leena; Vikkula, Johanna; Kreutzman, Anna; Engström-Risku, Mia; Kysenius, Kai; Hölsä, Olivia; Hernesniemi, Sari; Hemmilä, Päivikki; Pystynen, Anssi; Mäkelä, Siru
Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study (2024)
- Cancers
Virtanen, Saana; Pihlman, Heidi; Silvoniemi, Maria; Vihinen, Pia; Jaakkola, Panu; Mattila, Kalle E.
The impact of prognostic factors and comorbidities on survival in older adults with stage I − III cutaneous melanoma in Southwest Finland: A register study (2024)
- Journal of Geriatric Oncology
Mattila, Kalle E.; Vihinen, Helmi; Heervä, Eetu; Nuotio, Maria S.; Vihinen, Pia
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy (2023)
- Clinical Lung Cancer
Vihinen Hannes, Jokinen Artturi, Laajala Teemu D, Wahid Nesna, Peltola Lotta, Kettunen Tiia, Rönkä Aino, Tiainen Leena, Skyttä Tanja, Kohtamäki Laura, Tulokas Sanni, Karhapää Hanna, Hernberg Micaela, Silvoniemi Maria, Mattila Kalle E
Ei-melanoottisten ihosyöpien nykyhoito (2023)
- Duodecim
Mattila Kalle, Riihilä Pilvi, Veräjänkorva Esko, Mäkelä Siru